|Ph.D, 1996, Chemistry, Harvard, Boston, MA|
|Postdoctoral research: Massachusetts Institute of Technology, Boston, MA|
|Office:||University of Massachusetts Medical School
364 Plantation Street, LRB-619
Worcester, MA 01605
My research program is focused on the creation of improved genome editing technologies to facilitate both efficient and precise editing of vertebrate genomes. These improved nuclease technologies are being utilized in three areas of study: (1) developing reagents for precise gene correction/replacement that will be utilized for the gene therapy-based correction of monogenic diseases or the inactivation of integrated retroviral genomes; (2) engineering gene regulatory networks to deconvolute the signaling pathway that underpin cellular responses to external stimuli; and (3) improving reagents for the study of gene function in model organisms with a particular focus on zebrafish.
Improving the Precision of CRISPR/Cas9 nucleases for gene therapy applications:
We are working to develop new CRISPR/Cas nuclease systems that will efficiently and precisely target a single site within the genome. These modified nucleases will be utilized for specific gene correction approaches for various monogenic diseases. Development of these systems will begin in cell-culture model systems before being advanced into patient samples or animal disease models.
A position is available to apply artificial nucleases for the inactivation of HIV provirus (Click here for project details)
A technician position is available to participate in our gene editing efforts and to develop new tools for research in zebrafish (Click here for project details)